Laura Berner
Direttore/Membro del Consiglio presso BOLT BIOTHERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/05/2024
Provenienza dei contatti di primo grado di Laura Berner
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 19 | |
Trex Bio, Inc.
 Trex Bio, Inc. Pharmaceuticals: MajorHealth Technology Trex Bio, Inc. manufactures immunotherapies for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, CA.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Laura Berner tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Yale University | College/University | Undergraduate Degree Undergraduate Degree | |
Prestwick Pharmaceuticals, Inc.
 Prestwick Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prestwick Pharmaceuticals, Inc. develops drugs for diseases related to the central nervous system. Its drugs are used in curing diseases such as Huntington's, Parkinson's, restless legs syndrome, schizophrenia, autism, Alzheimer's, and sleep apnea diseases. The company was founded in 2002 and is headquartered in Washington DC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Semnur Pharmaceuticals, Inc.
 Semnur Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Semnur Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The firm focuses on the clinical and commercial development of products such as SP-102: a non-opioid epidural steroid injectable potentially for the treatment of Lumbosacral radicular pain. The company was founded by Mahendra G. Shah in 2013 and is headquartered in Mountain View, CA. | Pharmaceuticals: Major | Founder Director/Board Member | |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Real Estate Development | Corporate Officer/Principal Corporate Officer/Principal | |
| Stanford University School of Medicine | College/University | Doctorate Degree Corporate Officer/Principal | |
| SOLENO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Vivo Capital LLC
 Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | Investment Managers | Private Equity Investor Founder | |
NextWave Pharmaceuticals, Inc.
 NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| University of California, Berkeley | College/University | Undergraduate Degree Masters Business Admin | |
| Stanford Graduate School of Business | College/University | Masters Business Admin Masters Business Admin | |
| PFIZER, INC. | Pharmaceuticals: Major | Sales & Marketing Private Equity Investor | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| University of Montréal | College/University | Graduate Degree | |
Ontario Institute for Cancer Research
 Ontario Institute for Cancer Research Hospital/Nursing ManagementHealth Services Ontario Institute for Cancer Research provides research on the prevention, early detection, diagnosis, and treatment of cancer. It offers Innovation programs, like cancer stem cell, innovation in target validation, and smarter imaging, Technology programs, like drug discovery, genome technologies, informatics and bio-computing, imaging translation, and tranformative pathology, and Translation programs. The company was founded by Calvin R. Stiller in December 2005 and is headquartered in Toronto, Canada. | Hospital/Nursing Management | Chief Tech/Sci/R&D Officer | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| GILEAD SCIENCES, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| PHARMACYCLICS, INC. | Pharmaceuticals: Major | Founder | |
CDR-Life Inc.
 CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | Biotechnology | Director/Board Member | |
| BASILEA PHARMACEUTICA AG | Pharmaceuticals: Major | Director/Board Member | |
BIOCOM
 BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Decoy Biosystems, Inc.
 Decoy Biosystems, Inc. BiotechnologyHealth Technology Decoy Biosystems, Inc. provides cancer immunotherapy services. The company was founded on August 14, 2013 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member | |
Petra Pharma Corp.
 Petra Pharma Corp. Pharmaceuticals: MajorHealth Technology Petra Pharma Corp. operates as a drug development company that develops novel small molecules for the treatment of cancer and metabolic diseases. The company was founded by Lewis Clayton Cantley and Nathanael S. Gray in 2016 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member | |
| KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. | Pharmaceuticals: Major | Chief Executive Officer | |
Century Club of San Diego
 Century Club of San Diego Miscellaneous Commercial ServicesCommercial Services Century Club of San Diego engages in the promotion of golf events to support San Diego community and local youth programs. The company was founded in July 1961 and is headquartered in La Jolla, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Aquavit Pharmaceuticals, Inc.
 Aquavit Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquavit Pharmaceuticals, Inc. operates as a healthcare company that discovers, develops, and commercializes therapeutic products. It offers pharmaceuticals, nutraceuticals, and biologics. The company was founded in October 2010 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member | |
| The HENLEY College | College/University | Masters Business Admin | |
NBE-Therapeutics AG
 NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Director/Board Member | |
| ACUCELA INC | Pharmaceuticals: Major | Chief Executive Officer | |
Biopartners GmbH
 Biopartners GmbH Pharmaceuticals: MajorHealth Technology Biopartners GmbH engages in the development of biopharmaceutical products in the fields of endocrinology, multiple sclerosis, and virology. The company was founded in 2000 and is headquartered in Baar, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer | |
| COVANCE INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| NPS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| VIRACTA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| IMMUNOGEN, INC. | Biotechnology | Director/Board Member | |
Perseid Therapeutics LLC
 Perseid Therapeutics LLC Pharmaceuticals: MajorHealth Technology Perseid Therapeutics LLC was founded in September 2009 to discover and develop novel protein pharmaceuticals utilizing Molecular BreedingTM (also commonly referred to as DNA shuffling). It seeks to develop products that deliver significant patient benefit both by improving upon known protein therapies and also by discovering new therapeutic modalities. Perseid has initially focused its efforts treating disorders through therapeutics that modulate the immune system. Perseid Therapeutics is a joint venture between Maxygen, Inc. and Astellas Pharma Inc. with Maxygen owning approximately 83%, and Astellas Pharma owning the remaining approximately 17%. As part of the joint venture arrangement, Astellas has been granted an option until September of 2012 to acquire all of Perseid ownership at pre-specified prices that increase on a quarterly basis. The launch of Perseid completed Maxygen’s multi-year strategic process whereby most of Maxygen’s assets are in arrangements under which external parties are primarily responsible for funding. | Pharmaceuticals: Major | Chief Executive Officer | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree | |
| Columbia University College of Physicians & Surgeons | College/University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 38 |
| Svizzera | 7 |
| Canada | 3 |
| Regno Unito | 3 |
| Francia | 2 |
Settori
| Health Technology | 37 |
| Consumer Services | 10 |
| Finance | 3 |
| Commercial Services | 3 |
| Health Services | 2 |
Posizioni
| Director/Board Member | 188 |
| Independent Dir/Board Member | 55 |
| Corporate Officer/Principal | 53 |
| Founder | 27 |
| Chief Executive Officer | 27 |
Contatti più connessi
| Insiders | |
|---|---|
| James Healy | 50 |
| Carol Gallagher | 39 |
| Mahendra Shah | 34 |
| Kathy LaPorte | 34 |
| Edgar Engleman | 29 |
| Brian O'Callaghan | 20 |
| Nicole Onetto | 17 |
| Michael Baran | 14 |
| Frank Lee | 13 |
| Richard Miller | 13 |
| William Quinn | 11 |
| Randall Schatzman | 9 |
| Grant Yonehiro | 9 |
| Edith Perez | 9 |
| Debi Watson | 9 |
- Borsa valori
- Insiders
- Laura Berner
- Connessioni Società
